Tang, Patricia

Medical Oncology

Clinical Associate Professor

Web Presence:

https://pubmed.ncbi.nlm.nih.gov/?term=Tang%2C%20patricia%20a%5BAuthor%5D%20and%20cancer

Biography

Patricia Tang MD, FRCPC is a medical oncologist at the Arthur J. E. Child Comprehensive Cancer Centre and a Clinical Associate Professor at the Cumming School of Medicine, University of Calgary. She specializes in the treatment of breast and gastrointestinal malignancies.

After medical oncology residency at the University of Calgary, she completed an Investigational New Drug Fellowship at Princess Margaret Hospital, University of Toronto. As the Provincial Gastrointestinal Cancer Tumor Group Leader for Alberta, she is involved in development of clinical practice guidelines and pathways.   She is a co-investigator on numerous CIHR funded grants.  As the CCTG Center Representative, her academic focus is on clinical trials.  She currently serves on the pCODR Expert Review Committee.

Area of Focus

Early phase clinical trials

Summary of Research

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2025 Jul 3;393(1):13-25.
Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial. J Clin Oncol. 2026 Aug;44(22):2130-2139.
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2026 Mar 7;17(1):3631.
Real-World Study of the Implementation of Early and Systematic Palliative Care for Advanced Colorectal Cancer Care-The Palliative Care Early and Systematic Project. JCO Oncol Pract. 2025 Dec 12:OP2500492. doi: 10.1200/OP-25-00492
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022 Aug 26;13(1):5020.
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clin Colorectal Cancer. 2018 Sep;17(3):231-239.
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007 Oct 10;25(29):4562-8

Area Of Focus

Early phase clinical trials

Summary Of Research

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2025 Jul 3;393(1):13-25.
Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial. J Clin Oncol. 2026 Aug;44(22):2130-2139.
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2026 Mar 7;17(1):3631.
Real-World Study of the Implementation of Early and Systematic Palliative Care for Advanced Colorectal Cancer Care-The Palliative Care Early and Systematic Project. JCO Oncol Pract. 2025 Dec 12:OP2500492. doi: 10.1200/OP-25-00492
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022 Aug 26;13(1):5020.
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clin Colorectal Cancer. 2018 Sep;17(3):231-239.
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007 Oct 10;25(29):4562-8